ARID1A Gene Mutation clinical trials at UCSD

1 research study open to eligible people

NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
open to eligible people ages 18 years and up
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
La Jolla, California and other locations

Last updated: September 11, 2024

NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer